Shares of ASML slid 4.2% to €1,446.40 on the Frankfurt exchange, extending a weeklong decline of roughly 11%, even after the Dutch chipmaking-equipment monopoly posted the strongest quarter in its history and raised its outlook. The paradox captures a central tension for investors: demand has never been better, but the stock's price already assumed as much.

  • Record Quarter, and It Still Wasn't Enough for the Market

ASML generated €11.7 billion in Q3 sales — a record — with gross margins hitting 57.5%, well above its own guidance.

Earnings per share of $14.65 beat Wall Street's $12.13 consensus by nearly 21%. Yet the stock fell in regular trading and after hours, suggesting investors had already priced in much of the strength. When a company beats estimates by a wide margin and still sells off, the message is clear: the bar was set by the share price, not the analysts.

  • The Bottleneck That Cuts Both Ways

ASML said its chipmaking tool supply as currently planned for 2027 and 2028 will not fully meet customer demand.

CEO Christophe Fouquet said the company is "investigating ways to increase capacity for 2028 beyond the 30% increase we previously communicated." Being sold out for years sounds ideal — but if ASML cannot ship enough machines, some revenue simply gets pushed into later years, capping near-term upside. The company's inability to convert demand into deliveries fast enough is, ironically, what limits growth in the quarters investors care most about.

  • Customers Are Booking Into 2030 — A Vote of Confidence or Panic Buying?

Some customers are placing orders for 2029 and even 2030, as they expect their own supply will not meet demand at least until 2028. That gives ASML an extraordinarily long revenue runway. But some of that interest may reflect reservation behavior rather than firm orders — chipmakers hedging bets, not guaranteed spending.

  • Wall Street Is Split on What It's Worth

Barclays raised its price target to €2,500, Citigroup to €2,300, and HSBC to €2,261.

Jefferies trimmed its target to €1,590 and JPMorgan cut to $2,350, citing concern that capacity constraints limit how quickly ASML can turn exceptional demand into revenue.

One valuation model pegs ASML as roughly 29% overvalued at current levels. The core debate: does a company with no competitors and years of backlogged demand deserve a premium that already reflects much of that future — or is there still room to grow into the price?